Novo Nordisk A/S (NYSE:NVO) Hits New 1-Year Low – Here’s What Happened

Novo Nordisk A/S (NYSE:NVO) reached a new 52-week low on Monday . The company traded as low as $35.14 and last traded at $35.4710, with a volume of 474729 shares trading hands. The stock had previously closed at $36.04.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK cost‑effectiveness watchdog recommended use of Wegovy to reduce major heart risks in obese/overweight adults — the first GLP‑1 endorsed for this indication, which could broaden prescribing and boost long‑term demand. British drug-cost watchdog recommends use of Novo’s Wegovy to lower heart risks
• Positive Sentiment: Launched discounted multi‑month Wegovy subscriptions for U.S. self‑pay patients (up to ~30% off standard monthly rate) to improve access and predictable pricing — a defensive commercial move to regain share vs. Eli Lilly and to stabilize cash‑pay volumes. Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US
• Positive Sentiment: Company is executing a share repurchase programme (part of a previously announced DKK 15bn plan), which supports EPS and signals management confidence in the business. Novo Nordisk A/S – share repurchase programme
• Positive Sentiment: Completed a key China study for a new obesity/diabetes candidate — clinical progress in large markets can materially increase future upside. Novo Nordisk Advances New Obesity and Diabetes Drug With Key China Study Completion
• Positive Sentiment: Expanded distribution/affordability through partnerships (Hims telehealth GLP‑1 offering; Weight Watchers preferred pricing via NovoCare) — these broaden channels for self‑pay and insured patients. Hims GLP 1 Deal With Novo Nordisk Reshapes Growth And Valuation Story Weight Watchers Announces Best-in-Market Self-Pay Wegovy Pricing
• Neutral Sentiment: Company and rival Lilly are using AI across drug development to accelerate pipelines — a structural positive over the long term but not an immediate earnings driver. Lilly and Novo Show How AI Is Rewiring Big Pharma
• Negative Sentiment: Further deep price cuts in India for Ozempic and Wegovy (up to ~36–48%) to fend off local generics — helps retain volumes but pressures margins in a large market. Novo Nordisk further slashes prices of Ozempic, Wegovy in India
• Negative Sentiment: Planned layoffs at the Bloomington, Indiana manufacturing site (about 400 jobs) highlight cost‑cutting and operational reshaping; may be viewed negatively by some investors despite potential near‑term margin benefits. Novo Nordisk to lay off 400 Bloomington employees

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price objective on the stock. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. TD Cowen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a report on Tuesday, March 10th. HSBC reaffirmed a “hold” rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Four analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Trading Up 4.0%

The firm’s 50-day simple moving average is $44.90 and its 200 day simple moving average is $50.16. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The firm has a market capitalization of $163.90 billion, a price-to-earnings ratio of 10.58, a P/E/G ratio of 8.35 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 52.74%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Quotient Wealth Partners LLC boosted its stake in shares of Novo Nordisk A/S by 2.0% in the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after purchasing an additional 177 shares in the last quarter. Certuity LLC increased its position in Novo Nordisk A/S by 3.6% during the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after purchasing an additional 177 shares in the last quarter. Beacon Financial Group increased its position in Novo Nordisk A/S by 4.3% during the 3rd quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock worth $239,000 after purchasing an additional 178 shares in the last quarter. Oakworth Capital Inc. lifted its stake in Novo Nordisk A/S by 41.6% in the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after purchasing an additional 182 shares during the last quarter. Finally, True North Advisors LLC boosted its position in Novo Nordisk A/S by 3.9% in the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after buying an additional 199 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.